{"entity":{"id":"equecabtagene-autoleucel","kind":"drug","name":"Equecabtagene autoleucel","aka":[],"tldr":"Equecabtagene autoleucel is a BCMA CAR-T from IASO Bio and Innovent, approved in China in June 2023 for multiple myeloma that has returned after at least three lines of treatment. In the FUMANBA-1 trial about 96% of infused patients responded, most with deep minimal-residual-disease-negative remissions and few severe cytokine release reactions; it competes with cilta-cel and zevor-cel in China.","summary":"Developed by IASO Bio with Innovent from work at Tongji Hospital in Wuhan, and approved by the NMPA in June 2023 for relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory drug. The FUMANBA-1 trial (JAMA Oncology 2024) reported objective responses in about 96% of infused patients with deep, minimal residual disease-negative remissions and a low rate of severe cytokine release syndrome. It competes in China with ciltacabtagene autoleucel and zevorcabtagene autoleucel; it also holds FDA regenerative medicine advanced therapy designation.","status":"approved","asOf":"2026-09-10","links":[{"label":"IASO Biotherapeutics","url":"https://www.iasobio.com/"},{"label":"FUMANBA-1 (JAMA Oncol 2024)","url":"https://doi.org/10.1001/jamaoncol.2024.4879"},{"label":"Equecabtagene autoleucel: first approval (Mol Diagn Ther 2023)","url":"https://doi.org/10.1007/s40291-023-00673-y"}],"tags":["china"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["car-t"],"targets":["bcma"],"drugs":[],"companies":["iaso-bio","innovent"],"institutions":["tongji-hospital-wuhan"],"pathways":[],"terms":[],"trials":["fumanba-1","nct06464991"],"people":[],"bottlenecks":[],"keyPapers":["paper-li-jama-oncol","paper-keam-mol-diagn-ther"],"journals":[],"dependsOn":[],"notes":[],"brand":"Fucaso","code":"eque-cel, CT103A","modality":"Cell therapy (autologous BCMA CAR-T, fully human binder)","mechanism":"Autologous T cells expressing a fully human BCMA-directed single-chain variable fragment with 4-1BB co-stimulation, lentivirally transduced; the fully human binder is designed to reduce anti-CAR immunity and allow persistence.","approvals":[{"region":"China","year":2023,"indication":"Relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory agent"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/equecabtagene-autoleucel/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}],"company":[{"id":"iaso-bio","kind":"company","name":"IASO Biotherapeutics","route":"/companies/iaso-bio/"},{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}],"institution":[{"id":"tongji-hospital-wuhan","kind":"institution","name":"Tongji Hospital, Huazhong University of Science and Technology","route":"/institutions/tongji-hospital-wuhan/"}],"trial":[{"id":"nct06464991","kind":"trial","name":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","route":"/trials/nct06464991/"},{"id":"fumanba-1","kind":"trial","name":"FUMANBA-1","route":"/trials/fumanba-1/"}],"paper":[{"id":"paper-li-jama-oncol","kind":"paper","name":"Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial","route":"/key-papers/paper-li-jama-oncol/"},{"id":"paper-keam-mol-diagn-ther","kind":"paper","name":"Equecabtagene Autoleucel: First Approval","route":"/key-papers/paper-keam-mol-diagn-ther/"}],"person":[{"id":"yu-michael","kind":"person","name":"Michael Yu (Yu De-Chao)","route":"/people/yu-michael/"}]}}